io.net's $1 billion valuation comes at a time when demand for GPUs are skyrocketing and they provide on-demand GPU access.
IO Research's decentralized physical infrastructure network (DePIN), io.net, built on Solana, has reached a $1 billion fully diluted token valuation following its latest Series A funding round.
The rapid ascent of io.net's valuation marks an important moment in the democratization of computing resources, heralding a new era where AI and machine learning (ML) development are bound by fewer constraints.
This milestone arrives at a time when the demand for GPU computing power is skyrocketing. By leveraging decentralized networks like io.net, the industry can access a much-needed solution to the global GPU scarcity, ensuring the continued advancement of AI technologies without the hefty price tag.
io.net leverages the Solana blockchain for transparent proof-of-compute, enhancing transaction visibility between suppliers and consumers. The IO token facilitates a unified transaction experience and incentivizes network participation and growth, claiming to reduce cloud AI costs by up to 90% for customers in the face of a global GPU shortage.
"Io.net saves customers up to 90% on their cloud AI costs. In an age where GPU chips are in high demand with global shortages, that is simply an incredible accomplishment," stated Ed Roman, managing partner at Hack VC.
With the native IO token set to launch on April 28, the future looks bright for io.net. The platform is poised for significant growth, aiming to double its workforce by year-end to accelerate development and meet escalating demand. This expansion is a testament to io.net's potential to revolutionize how we approach GPU computing for AI and ML.
The innovative use of blockchain for proof-of-compute ensures transparency and efficiency, exemplifying how decentralized solutions can overcome traditional barriers in technology sectors. io.net's model could serve as a blueprint for future endeavors aiming to tackle similar challenges across various industries.
io.net exemplifies the transformative power of decentralization in technology, achieving a $1 billion token valuation that not only signifies financial success but also highlights a significant shift towards more accessible and affordable computing resources. Platforms like io.net are essential in ensuring these technologies can grow unencumbered by current limitations.
<script type="application/ld+json">
{
"@context": "https://schema.org",
"@type": "Article",
"mainEntityOfPage": {
"@type": "WebPage",
"@id": "https://www.themoney.game/stories/depins-billion-dollar-breakthrough"
},
"headline": "DePIN's Billion Dollar Breakthrough",
"description": "io.net's $1 billion valuation comes at a time when demand for GPUs are skyrocketing and they provide on-demand GPU access.",
"image": "",
"author": {
"@type": "Organization",
"name": "The Money Game",
"url": "https://www.themoney.game"
},
"publisher": {
"@type": "Organization",
"name": "",
"logo": {
"@type": "ImageObject",
"url": ""
}
},
"datePublished": "2024-03-08"
}
</script>
Actions
Pages
Subscribe for newsletter
Stories
Italian space logistics startup D-Orbit has raised $110 million for their satellite deployment and space operations business. The investment is led by Marubeni Corporation from Japan's industrial sector, with participation from various other investors.
D-Orbit provides last-mile satellite delivery, mission control services, and space waste management. The company's model involves a combination of software and hardware development and caters to both government and commercial space projects.
As a logistics provider for companies in the space industry, the company claims that its operational model saves 40% on costs and 85% on time by grouping multiple customers together and bulk-procuring around launches.
D-Orbit's founders, trained as engineers with expertise in space propulsion, flight dynamics, and aerodynamics, envision expanding their services to connect Mars, the asteroid belt, the moon, and Earth through a logistics network. The company also aims to contribute to the circular economy in space technology by addressing the growing issue of space debris through methods like decommissioning satellites and repurposing satellite parts in orbit.
Story
Finnish biotech startup Enifer has secured a €12 million grant from the European Union’s NextGenerationEU programme to pioneer the world's first commercial-scale PEKILO® mycoprotein technology, converting industrial by-products into a high-quality, sustainable protein source.
The alternative protein market is expected to reach $423 billion by 2033, driven by global environmental and health awareness. Enifer's technology taps into this burgeoning market, offering alternative protein with at least 20 times lower carbon emissions compared to traditional protein sources.
“This plant will be a critical stepping stone to scaling the production of PEKILO® as a truly universal protein source – which we aim to commercialize globally across different applications,” shares Simo Ellilä, CEO and co-founder of Enifer.
Enifer's immediate focus includes completing the factory by the end of 2025, scaling up production in 2026, and anticipating regulatory approval for food-grade mycoprotein by 2024, setting the stage for a wider market launch.
Story
Moonwalk Biosciences, co-founded by CRISPR pioneer Feng Zhang and former Illumina CTO Alex Aravanis, has secured $57 million in funding to advance gene therapy with its epigenetic editing technology.
The gene therapy market, set to surge from $7.18 billion in 2024 to $24.67 billion by 2029, continues to innovate with Moonwalk's non-invasive epigenetic editing. This method, targeting epigenetic modifications over DNA alteration, provides safer, more effective treatments for chronic and aging-related diseases.
“Epigenetics is the software of the genome. While changes to the genome are irreversible, edits to the epigenome can be reprogrammed in different ways. Epigenetic changes determine whether genes are turned on or off, and can potentially reverse disease, broadening the therapeutic landscape to find potential cures previously thought impossible,” said Alex Aravanis, M.D., Ph.D., CEO and Co-Founder, Moonwalk Biosciences.
The next steps include clinical trials to validate the safety and efficacy of its epigenetic editing technique. As this technology advances, it could challenge the industry's belief that traditional gene editing, such as CRISPR-Cas9, is the only path forward for gene therapy.
Moonwalk's approach, utilizing AI for predicting epigenetic targets, leverages the body's natural regulation system, offering a nuanced approach to gene control. This resonates with the trend in biotechnology towards precision and personalization, moving away from one-size-fits-all solutions.
Story
Innovators
Scroll
Open
Close